Suominen’s Q4 was expected to show some further recovery in earnings, but its pace still turned out ...
Suominen’s result were largely in line with Q3 and fell short of Vara Research consensus expectation...
Redeye sees a Q4 with sales coming in according to our estimates, but we note that costs came in hig...
EBIT +5% vs. ABGSCe, 21% org. growth, 39% margins (ABGSCe 36%) Slightly slower ramp-up vs.
Redeye retains its positive view on Lagercrantz following a Q3 report in-line with our estimates.
Redeye comments on GiG ahead of its Q4-results (due 14 February) where we expect the company to deli...
Redeye was surprised, not to say shocked, to see the Acconeer press release of a wipeout rights issu...
Q4: Clean EBIT of SEK -100m Pulp prices up and demand better Fair value range: SEK 9-16/sh Q4: Figu...
Redeye comments on Artificial Solution's announcement of the outcome of the rights issue.
Analyst Group has entered into an agreement with Pharma Equity Group on commissioned research, inclu...
Enersense will build three 110kV power grid substations in Finland.
Equity analyst interviews Elanders' CEO Magnus Nilsson and CFO Andreas Wikner after their Q4.
Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and ...
A SEK 20m to SEK 35m financing based with the financial partner Formue Nord Fokus A/S eases the fina...
Vast majority of inventory normalisation... ...likely to be completed in the coming 6-9 months '23e-...
Having already achieved proof-of-performance for its proprietary digital technique for detection of ...
Consti’s Q4 figures missed our estimates mainly due to lower volumes than expected.
Redeye updates its estimates and valuation following Lifco’s Q4 2023 report.
Redeye views the bounce back for Tagmaster after a weak Q3 report as encouraging.
Ferronordic will report its Q4 2023 results on 22 February.